Skip to main content
iNtRON Biotechnology, Inc. logo

iNtRON Biotechnology, Inc. — Investor Relations & Filings

Ticker · 048530 ISIN · KR7048530000 KO Manufacturing
Open in API
Filings indexed 268 across all filing types
Latest filing 2022-03-07 Director's Dealing
Country KR South Korea
Listing KO 048530

About iNtRON Biotechnology, Inc.

https://intronbio.com:6001

iNtRON Biotechnology, Inc. is a biotechnology company specializing in solutions for infectious diseases. Its core activities are centered on three main pillars: bio-new drugs, molecular diagnostics, and molecular biology reagents. The company's therapeutic pipeline focuses on developing novel treatments for drug-resistant super-bacteria, creating antibiotic alternatives and other bio-active agents to address the challenge of antimicrobial resistance (AMR). In its diagnostics division, iNtRON develops and manufactures detection kits and assays, primarily based on real-time PCR technology, for the rapid identification of infectious organisms. The company also provides a range of molecular reagents for research and has commercialized antibiotic alternative products for the animal health market.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details share acquisitions by an executive (Yoon Kyung Won) of Intron Biotechnology. This is a standard regulatory filing for insider trading/director dealings, which corresponds to the 'Director's Dealing' category.
2022-03-07 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under Article 147 of the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties (insiders) of Intron Biotechnology. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks significant ownership thresholds and changes.
2022-03-07 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system (KIND) regarding a significant change in revenue or profit structure (30% or more). This is a standard disclosure requirement for listed companies in Korea to report preliminary financial results or material changes in financial performance. Since it provides the initial announcement of financial results (key highlights) rather than a full annual report or a transcript, it falls under the Earnings Release category. FY 2021
2022-02-17 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Report' (영업(잠정)실적) for Intron Biotechnology. It provides a summary table of revenue, operating profit, and net income for the 4th quarter of 2021 compared to previous periods. This is a standard initial announcement of financial results, which fits the definition of an Earnings Release (ER). Q4 2021
2022-02-09 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Intron Biotechnology. It outlines the date, location, agenda items (financial statement approval, director appointments, remuneration limits), and details regarding electronic voting. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the upcoming meeting and the matters to be voted upon.
2022-02-08 Korean
전환가액의조정
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing regarding the adjustment of the conversion price for convertible bonds (CB) issued by Intron Biotechnology. It details the change in conversion price, the number of convertible shares, the reason for the adjustment (market price decline), and the calculation methodology. This type of disclosure regarding capital structure changes and debt-to-equity conversion terms falls under 'Capital/Financing Update'.
2022-02-03 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.